Wegovy contains semaglutide, a GLP-1 receptor agonist that was initially developed for type 2 diabetes management and is now licensed for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities
Many medications, especially those that are biologically derived or contain sensitive compounds, require refrigeration to maintain their efficacy and safety
Results vary, but many patients begin to notice weight loss within the first few weeks
For decades, this rapid enzymatic degradation led many clinicians to believe that oral glutathione supplementation was largely ineffective for raising intracellular levels
According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, an estimated 19.8% of Egyptian adults aged 2079 years are living with diabetes, with an age-adjusted comparative prevalence of 22.4%
However, there were limitations in directly comparing each study because there are cases in which the subjects were PCOS women and mice, and the generation of Rotterdam Criteria, which is the main criteria for the subjects PCOS diagnosis, was also different